SCHEMBL3227634

SCHEMBL3227634

CCOC(=O)Cc1ccc(-c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.58
LMNA P02545 2/20 0.58
ABCC4 O15439 1/20 0.58
TSHR P16473 1/20 0.58
PTGS1 P23219 1/20 0.58
HTT P42858 1/20 0.58
L3MBTL1 Q9Y468 3/20 0.58
ALDH1A1 P00352 3/20 0.58
THRB P10828 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.57
NPC1 O15118 1/20 0.57
PKM P14618 1/20 0.57
NFKB1 P19838 1/20 0.57
RAB9A P51151 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
TRPM8 Q7Z2W7 1/20 0.55
MAPK1 P28482 1/20 0.55
PAM P19021 1/20 0.53
MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7390203 0.98 L3MBTL1 (0.56) GAALMNAABCC4TSHRPTGS1
SCHEMBL68930 0.93 CYP4Z1 (0.57) GAALMNATSHRL3MBTL1ALDH1A1
SCHEMBL7761585 0.89 L3MBTL1 (0.49) GAALMNAABCC4TSHRPTGS1
Benzene SCHEMBL28160801 0.89 ALDH1A1 (0.68) LMNATSHRL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1873977 0.89 ALDH1A1 (0.68) LMNATSHRL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL112999 0.89 ALDH1A1 (0.68) LMNATSHRL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1332625 0.89 ALDH1A1 (0.68) LMNATSHRL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL12126600 0.87 CYP4Z1 (0.53) LMNATSHRHTTL3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL28243605 0.87 ALDH1A1 (0.66) LMNATSHRL3MBTL1ALDH1A1SMN1; SMN2
Water SCHEMBL27679105 0.87 ALDH1A1 (0.66) LMNATSHRL3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120131972-A Microsatellite stabilized colorectal cancer combination therapy based on PCSK9 inhibitors 广东省人民医院 2025-06-13 CN claimed
CN-118987016-A Application of antisense oligonucleotide in preparing medicament for treating glioma 北京悦康科创医药科技股份有限公司 2024-11-22 CN claimed
EP-0171084-B1 PHARMACEUTICAL OIL-IN-WATER TYPE MICRO-EMULSION LEDERLE (JAPAN) LTD. (JP) 1991-06-05 EP claimed
US-4647586-A BIPHENYLACETIC ACID ESTER LEDERLE (JAPAN), LTD. (JP) 1987-03-03 US claimed
EP-0171084-A2 Pharmaceutical oil-in-water type micro-emulsion LEDERLE (JAPAN) LTD. (JP) 1986-02-12 EP claimed
CN-122009643-A Automatic feeding control system and control method for labeling machine 台州奇优家居用品有限公司 2026-05-12 CN disclosed
US-20260069707-A1 COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES HALOZYME, INC. (US) 2026-03-12 US disclosed
EP-4702053-A1 COMBINATION TREATMENT TARGETING SIRPA AND CLAUDIN 18.2 LaNova Medicines Limited (CN) 2026-03-04 EP disclosed
EP-4682164-A1 NOVEL FUSION PROTEIN FOR TREATING AUTOIMMUNE DISEASES Curogen Technology Co., Ltd. (KR) 2026-01-21 EP disclosed
EP-4662241-A1 ANTIBODIES TARGETING LIV-1 AND USES THEREOF LaNova Medicines Limited (CN) 2025-12-17 EP disclosed
EP-4659068-A1 DISPLAY SYSTEMS COMPRISING SPACERS DISPOSED BETWEEN FRAME AND DISPLAY BACK PANEL AND ASSOCIATED METHODS Corning Incorporated (US) 2025-12-10 EP disclosed
EP-4656011-A2 STABLE THIN FILM HEATERS BASED ON TRANSPARENT CONDUCTIVE COATINGS, STRUCTURES FORMED WITH THE HEATERS AND APPLICATIONS THEREOF EKC TECHNOLOGY, INC. (US) 2025-12-03 EP disclosed
US-5231089-A Anticonvulsants for nervous system disorders UNIVERSITY OF FLORIDA (US) 1993-07-27 US disclosed
WO-1993010794-A1 COMPOSITION AND METHOD FOR IMPROVING ORAL BIOAVAILABILITY OF CARBAMAZEPINE UNIVERSITY OF FLORIDA (US) 1993-06-10 WO disclosed
US-5024998-A Administering in aqueous solution with cyclodextrin derivative UNIVERSITY OF FLORIDA (US) 1991-06-18 US disclosed
EP-0171084-B1 PHARMACEUTICAL OIL-IN-WATER TYPE MICRO-EMULSION LEDERLE (JAPAN) LTD. (JP) 1991-06-05 EP disclosed
US-5017566-A Redox systems for brain-targeted drug delivery UNIVERSITY OF FLORIDA (US) 1991-05-21 US disclosed
US-4647586-A BIPHENYLACETIC ACID ESTER LEDERLE (JAPAN), LTD. (JP) 1987-03-03 US disclosed
EP-0171084-A2 Pharmaceutical oil-in-water type micro-emulsion LEDERLE (JAPAN) LTD. (JP) 1986-02-12 EP disclosed
EP-0036684-A1 Derivatives of 4-methyl-5-(2-aminoethyl)-thiomethyl-imidazole having therapeutic activity Turconi, Franco (IT) 1981-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260069707-A1 COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES CD22, CD2, CD44 GAA 1129/4885LMNA 2796/4885ABCC4 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.